The real revolution came in 2012, when researchers Jennifer Doudna and Emmanuelle Charpentier harnessed CRISPR, a natural bacterial defense system. In bacteria, CRISPR cuts out invading viruses’ DNA ...
According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...
AgroNetica, a leader in applying CRISPR technology for cacao, today unveils its revolutionary "super-cacao" project. While other companies focus on solving individual problems in Chocolate, AgroNetica ...
ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company ...
By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
TipRanks on MSN
CRISPR Therapeutics Reports Q3 2025 Financial Results
Crispr Therapeutics ( ($CRSP) ) has released its Q3 earnings. Here is a breakdown of the information Crispr Therapeutics presented to its ...
CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback